Verdict Boosts Amgen
Roche won't be allowed to sell Mircera, its rival medicine to Amgen's Aranesp and Epogen, in the U.S.
A jury voted in favor of
Amgen
(AMGN) - Get Report
Tuesday in a patent dispute case, according to a
Bloomberg
report.
The ruling determines in effect that
Roche
may not sell Mircera, its rival medicine to Amgen's Aranesp and Epogen anemia drugs, in the U.S.
Amgen shares were rising 87 cents, or 1.6%, to $56.99 in recent trading.
Loading ...